- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Bethlehem Today
By the People, for the People
OraSure Technologies Misses Q4 Earnings Expectations
Medical device maker reports $0.21 loss per share, missing analyst estimates by $0.04
Feb. 25, 2026 at 10:59pm
Got story updates? Submit your updates here. ›
OraSure Technologies (NASDAQ:OSUR), a medical instruments supplier, reported its Q4 2025 earnings results on Wednesday. The company reported a loss of $0.21 per share, missing analysts' consensus estimates of a $0.17 loss per share by $0.04. OraSure had a negative return on equity of 13.61% and a negative net margin of 47.92% for the quarter.
Why it matters
OraSure's earnings miss highlights the continued challenges the company is facing as it works to develop and commercialize new diagnostic tests. The company's core business has struggled in recent quarters, putting pressure on its financial performance. Investors will be watching closely to see if OraSure can execute on its pipeline of new product launches and return to profitability.
The details
In its earnings report, OraSure said it submitted two FDA applications in December for a rapid molecular OTC self-test for chlamydia/gonorrhea (Sherlock) and an at-home urine collection device, targeting mid-year 2026 launches. The company also cited a total addressable market (TAM) of over $1.5 billion for these products. Additionally, OraSure said international diagnostics trends are stabilizing, and it is pursuing nearshoring (in-country assembly in Africa) and integrating BioMedomics to expand distribution of its Sickle SCAN test, with revenue contributions expected beginning in Q1 2026.
- OraSure Technologies reported its Q4 2025 earnings results on Wednesday, February 25, 2026.
- The company submitted two FDA applications in December 2025 for new diagnostic tests, targeting mid-year 2026 launches.
The players
OraSure Technologies
A Bethlehem, Pennsylvania-based medical instruments supplier specializing in the development, manufacture and commercialization of point-of-care and self-testing products.
What’s next
OraSure Technologies expects to achieve operating cash flow breakeven by 2027 as it works to improve gross margins and drive revenue growth from its new diagnostic test launches.
The takeaway
OraSure's earnings miss underscores the ongoing challenges the company faces as it transitions its business. While the company has a pipeline of new products, investors will be closely watching to see if OraSure can successfully execute on its growth plans and return to profitability.
